Results 1 to 10 of about 128,690 (394)

Cholangiocarcinoma [PDF]

Pathologica, 2021
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar and distal.
P. Brindley, Melinda Bachini, S. Ilyas, Shahid A. Khan, A. Loukas, A. Sirica, B. Teh, S. Wongkham, Gregory J. Gores   +8 more
semanticscholar   +13 more sources

Surgery for cholangiocarcinoma [PDF]

Liver International, 2019
Surgical resection is the only potentially curative treatment for patients with cholangiocarcinoma. For both perihilar cholangiocarcinoma (pCCA) and intrahepatic cholangiocarcinoma (iCCA), 5‐year overall survival of about 30% has been reported in large ...
U. Cillo, C. Fondevila, M. Donadon, E. Gringeri, F. Mocchegiani, H. Schlitt, J. Ijzermans, M. Vivarelli, K. Zieniewicz, S. O. Olde Damink, B. Groot Koerkamp   +10 more
semanticscholar   +4 more sources

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation [PDF]

, 1998
Background: Because of the rarity of hilar cholangiocarcinoma, its prognostic risk factors have not been sufficiently analyzed. This retrospective study was undertaken to evaluate various pathologic risk factors which influenced survival after curative ...
Dvorchik, I, Fung, JJ, Iwatsuki, S, Lee, RG, Madariaga, JR, Marsh, JW, Starzl, TE, Todo, S   +7 more
core   +3 more sources

Pathogenesis of Cholangiocarcinoma.

Annual Review of Pathology: Mechanisms of Disease, 2020
Cholangiocarcinoma (CCA) encompasses a group of malignancies that can arise at any point in the biliary tree. Although considered a rare cancer, the incidence of CCA is increasing globally. The silent and asymptomatic nature of these tumors, particularly
P. Rodrigues, P. Olaizola, N. Paiva, I. Olaizola, Aloña Agirre-Lizaso, A. Landa, L. Bujanda, M. Perugorria, J. Banales   +8 more
semanticscholar   +3 more sources

Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles [PDF]

PeerJ, 2022
Background Cholangiocarcinoma (CCA) is a malignancy of the cholangiocytes. One of the major issues regarding treatment for CCA patients is the development of chemotherapeutic resistance.
Sirinya Sitthirak, Manida Suksawat, Jutarop Phetcharaburanin, Arporn Wangwiwatsin, Poramate Klanrit, Nisana Namwat, Narong Khuntikeo, Attapol Titapun, Apiwat Jarearnrat, Sakkarn Sangkhamanon, Watcharin Loilome   +10 more
doaj   +2 more sources

Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells [PDF]

PeerJ, 2023
Background Niclosamide is an oral anthelminthic drug that has been used for treating tapeworm infections. Its mechanism involves the disturbance of mitochondrial membrane potential that in turn inhibits oxidative phosphorylation leading to ATP depletion.
Thanaporn Kulthawatsiri, Yingpinyapat Kittirat, Jutarop Phetcharaburanin, Jittima Tomacha, Bundit Promraksa, Arporn Wangwiwatsin, Poramate Klanrit, Attapol Titapun, Watcharin Loilome, Nisana Namwat   +9 more
doaj   +2 more sources

1H NMR fecal metabolic phenotyping of periductal fibrosis- and cholangiocarcinoma-specific metabotypes defining perturbation in gut microbial-host co-metabolism [PDF]

PeerJ, 2023
Background The liver fluke Opisthorchis viverrini (OV), which subsequently inhabits the biliary system and results in periductal fibrosis (PDF), is one of the primarily causes of cholangiocarcinoma (CCA), a bile duct cancer with an exceptionally high ...
Rujikorn Treeriya, Phuc N. Ho, Attapol Titapun, Poramate Klanrit, Manida Suksawat, Thanaporn Kulthawatsiri, Suphasarang Sirirattanakul, Watcharin Loilome, Nisana Namwat, Arporn Wangwiwatsin, Nittaya Chamadol, Narong Khuntikeo, Jutarop Phetcharaburanin   +12 more
doaj   +2 more sources

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

New England Journal of Medicine, 2023
BACKGROUND Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, J. Valle, C. Morizane, T. Karasic, T. Abrams, J. Furuse, R. Kelley, P. Cassier, H. Klümpen, H. Chang, Li-Tzong Chen, J. Tabernero, Do-Youn Oh, A. Mahipal, M. Moehler, E. Mitchell, Y. Komatsu, Kunihiro Masuda, Daniel H Ahn, R. Epstein, A. Halim, Yao Fu, T. Salimi, V. Wacheck, Yaohua He, Mei Liu, K. Benhadji, J. Bridgewater   +29 more
semanticscholar   +1 more source

Modification of the eighth AJCC/UICC staging system for perihilar cholangiocarcinoma: An alternative pathological staging system from cholangiocarcinoma-prevalent Northeast Thailand

Frontiers in Medicine, 2022
AimThis study aims to improve the classification performance of the eighth American Joint Committee on Cancer (AJCC) staging system for perihilar cholangiocarcinoma (pCCA) by proposing the Khon Kaen University (KKU) staging system developed in ...
Chaiwat Aphivatanasiri, Chaiwat Aphivatanasiri, Chaiwat Aphivatanasiri, Prakasit Sa-Ngiamwibool, Prakasit Sa-Ngiamwibool, Prakasit Sa-Ngiamwibool, Sakkarn Sangkhamanon, Sakkarn Sangkhamanon, Sakkarn Sangkhamanon, Piyapharom Intarawichian, Piyapharom Intarawichian, Piyapharom Intarawichian, Waritta Kunprom, Waritta Kunprom, Waritta Kunprom, Malinee Thanee, Malinee Thanee, Malinee Thanee, Piya Prajumwongs, Piya Prajumwongs, Piya Prajumwongs, Narong Khuntikeo, Narong Khuntikeo, Narong Khuntikeo, Attapol Titapun, Attapol Titapun, Attapol Titapun, Apiwat Jareanrat, Apiwat Jareanrat, Apiwat Jareanrat, Vasin Thanasukarn, Vasin Thanasukarn, Vasin Thanasukarn, Tharatip Srisuk, Tharatip Srisuk, Tharatip Srisuk, Vor Luvira, Vor Luvira, Vor Luvira, Kulyada Eurboonyanun, Kulyada Eurboonyanun, Kulyada Eurboonyanun, Julaluck Promsorn, Julaluck Promsorn, Julaluck Promsorn, Watcharin Loilome, Watcharin Loilome, Watcharin Loilome, Aileen Wee, Supinda Koonmee, Supinda Koonmee, Supinda Koonmee   +51 more
doaj   +1 more source

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

JAMA Oncology, 2021
Key Points Question Does ivosidenib treatment improve overall survival outcomes vs placebo among patients with chemotherapy-refractory cholangiocarcinoma with IDH1 mutation?
A. Zhu, T. Macarulla, M. Javle, R. Kelley, S. Lubner, J. Adeva, J. Cleary, D. Catenacci, M. Borad, J. Bridgewater, W. Harris, A. Murphy, D. Oh, J. Whisenant, M. Lowery, L. Goyal, R. Shroff, A. El-Khoueiry, Christina X. Chamberlain, E. Aguado-Fraile, S. Choe, Bin Wu, Hua Liu, C. Gliser, S. Pandya, J. Valle, G. Abou-Alfa   +26 more
semanticscholar   +1 more source